Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection

Aleks Guvenel, Agnieszka Jozwik, Stephanie Ascough, Seng Kuong Ung, Suzanna Paterson, Mohini Kalyan, Zoe Gardener, Emma Bergstrom, Satwik Kar, Maximillian S Habibi, Allan Paras, Jie Zhu, Mirae Park, Jaideep Dhariwal, Mark Almond, Ernie Hc Wong, Annemarie Sykes, Jerico Del Rosario, Maria-Belen Trujillo-Torralbo, Patrick Mallia, John Sidney, Bjoern Peters, Onn Min Kon, Alessandro Sette, Sebastian L Johnston, Peter J Openshaw, Christopher Chiu, Aleks Guvenel, Agnieszka Jozwik, Stephanie Ascough, Seng Kuong Ung, Suzanna Paterson, Mohini Kalyan, Zoe Gardener, Emma Bergstrom, Satwik Kar, Maximillian S Habibi, Allan Paras, Jie Zhu, Mirae Park, Jaideep Dhariwal, Mark Almond, Ernie Hc Wong, Annemarie Sykes, Jerico Del Rosario, Maria-Belen Trujillo-Torralbo, Patrick Mallia, John Sidney, Bjoern Peters, Onn Min Kon, Alessandro Sette, Sebastian L Johnston, Peter J Openshaw, Christopher Chiu

Abstract

BACKGROUNDRespiratory syncytial virus (RSV) is an important cause of acute pulmonary disease and one of the last remaining major infections of childhood for which there is no vaccine. CD4+ T cells play a key role in antiviral immunity, but they have been little studied in the human lung.METHODSHealthy adult volunteers were inoculated i.n. with RSV A Memphis 37. CD4+ T cells in blood and the lower airway were analyzed by flow cytometry and immunohistochemistry. Bronchial soluble mediators were measured using quantitative PCR and MesoScale Discovery. Epitope mapping was performed by IFN-γ ELISpot screening, confirmed by in vitro MHC binding.RESULTSActivated CD4+ T cell frequencies in bronchoalveolar lavage correlated strongly with local C-X-C motif chemokine 10 levels. Thirty-nine epitopes were identified, predominantly toward the 3' end of the viral genome. Five novel MHC II tetramers were made using an immunodominant EFYQSTCSAVSKGYL (F-EFY) epitope restricted to HLA-DR4, -DR9, and -DR11 (combined allelic frequency: 15% in Europeans) and G-DDF restricted to HLA-DPA1*01:03/DPB1*02:01 and -DPA1*01:03/DPB1*04:01 (allelic frequency: 55%). Tetramer labeling revealed enrichment of resident memory CD4+ T (Trm) cells in the lower airway; these Trm cells displayed progressive differentiation, downregulation of costimulatory molecules, and elevated CXCR3 expression as infection evolved.CONCLUSIONSHuman infection challenge provides a unique opportunity to study the breadth of specificity and dynamics of RSV-specific T-cell responses in the target organ, allowing the precise investigation of Trm recognizing novel viral antigens over time. The new tools that we describe enable precise tracking of RSV-specific CD4+ cells, potentially accelerating the development of effective vaccines.TRIAL REGISTRATIONClinicalTrials.gov NCT02755948.FUNDINGMedical Research Council, Wellcome Trust, National Institute for Health Research.

Keywords: Adaptive immunity; Immunology; Infectious disease; T cells.

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1. Flow diagram outlining study design…
Figure 1. Flow diagram outlining study design and participating subjects.
(A) Healthy adult volunteers (n = 49) were enrolled and inoculated with RSV M37 for polyclonal CD4+ T cell analysis and epitope discovery. (B) A second cohort (n = 8) was enrolled for tetramer analysis of RSV-specific CD4+ T cells.
Figure 2. Enrichment of activated and regulatory…
Figure 2. Enrichment of activated and regulatory CD4+ T cells in the lower airway during RSV infection.
(A) Whole blood (n = 49) and BAL (n = 24) samples were stained with anti-CD3, -CD4, -CD8, -CD38, and –Ki-67 for analysis by flow cytometry. Plots are gated on CD3+CD4+ lymphocytes. One representative infected subject is shown for blood (upper panels) and BAL (lower panels). Median and individual data points of Ki-67+CD38+CD4+ T cells in the (B) blood and (C) BAL of infected (PCR+, red) or uninfected (PCR–, blue) volunteers are shown. Tests of the 5 a priori hypotheses were conducted by Wilcoxon’s signed-rank test with Bonferroni-adjusted α levels of 0.01 (**P < 0.001). (D) Frequencies of Ki-67+CD38+ cells on day 10 after infection are compared between paired blood and BAL samples in infected individuals (n = 12). Tests of the 5 a priori hypotheses were conducted by Wilcoxon’s signed-rank test with Bonferroni-adjusted α levels of 0.01 with no statistically significant differences seen. (E) Whole blood and BAL samples were stained with anti-CD3, -CD4, -FoxP3, and -CD25. One representative infected BAL sample is shown gated on CD3+CD4+ lymphocytes. (F) Mean and individual data points of FoxP3+CD25+CD4+ T cells in the blood and BAL of infected (PCR+, red circles) or uninfected (PCR–, blue squares) volunteers are shown. P values for Wilcoxon’s signed-rank (intragroup) and Mann-Whitney tests (intergroup) are shown. *P < 0.05.
Figure 3. Activated CD4 + T cell…
Figure 3. Activated CD4+ T cell frequencies in the lower airway correlate strongly with CXCL10 expression.
(A) CD4+ cells (brown) were identified in bronchial biopsies (n = 12) by immunohistochemistry and enumerated in infected individuals. Scale bars: 20 μm. Individual data points are presented as number of positive cells per square millimeter of subepithelium or per 0.1 mm2 of epithelium. *P < 0.05 by Wilcoxon’s signed-rank test. (B) Differential cytokine and chemokine gene expression in bronchial brushings 7 days after infection compared with preinfection was analyzed by RT2 Profiler qPCR array. Greater than 2-fold upregulated (red) and downregulated (green) genes are shown. (C) Mean ± SEM gene expression levels of CXCL9, CXCL10, and CXCL11 are shown in infected (red) and uninfected (green) individuals. (D) Spearman’s correlations between bronchial mucosal lining fluid CXCL10 or CXCL11 concentrations and the frequency of Ki-67+CD38+CD4+ T cells in BAL are shown.
Figure 4. CD69 + resident memory CD4…
Figure 4. CD69+ resident memory CD4+ T cells in BAL exhibit advanced differentiation.
Whole blood/PBMCs (n = 10) and BAL (n = 5) from individuals infected with RSV were costained with anti-CD3, -CD4, and phenotypic markers and then analyzed by flow cytometry. (A) CD69 and CD103 as canonical markers of resident memory T cells are shown in blood and BAL from infected volunteers. Mean ± SEM frequencies are shown. (B) Memory markers CD45RA and CCR7, (C) costimulatory markers CD27 and CD28, (D) homing markers CCR5 and CD62L, and (E) cytotoxicity markers perforin and granzyme B are shown in blood and BAL. In CD69+ (Trm) and CD69– (non-Trm) subsets from BAL, frequencies of (F) CCR5 and CD62L, (G) CD45RA and CCR7, and (H) CD27 and CD28-expressing CD4+ T cell are shown. P values for paired t test are shown. **P < 0.01.
Figure 5. RSV-specific CD4 + T cells…
Figure 5. RSV-specific CD4+ T cells primarily express 1 or 2 Th1 cytokines.
(A) PBMCs from RSV-challenged subjects (n = 18) were assayed by IFN-γ ELISpot stimulated with whole RSV. Median and individual data points are shown with P values for 2-tailed Mann-Whitney test comparing infected and uninfected groups, and 2-tailed Wilcoxon’s matched-pairs tests comparing time points. ***P < 0.001. (B) Median and IQR of T helper cell subsets expressing different cytokines are shown. (CE) PBMCs from infected subjects (n = 10) on day 10 after infection were cultured in vitro with live RSV or media for 24 hours and Brefeldin A added 4 hours before staining with fixable viability dye and with antibodies against CD3, CD4, and (C) IFN-γ, IL-2, and TNF; (D) IL-4, IL-5; or (E) IL-17A and IL-17F. Representative FACS plots from a single participant are shown.
Figure 6. Immunodominant CD4 + T cell…
Figure 6. Immunodominant CD4+ T cell epitopes are found in the surface F and G proteins.
Fresh PBMCs from individuals infected with RSV (n = 10) were assayed by IFN-γ ELISpot using overlapping peptides covering the RSV proteome. (A) ELISpot responses to peptide pools on days 0, 10, and 28 after infection are arranged according to the originating protein. (B) Total ELISpot responses to peptide pools on days 0, 10, and 28 after infection are shown. Median and individual counts are shown with P values for 2-tailed Wilcoxon’s matched-pairs tests comparing time points. (C) Median and IQR ELISpot responses to each peptide pool are shown in RSV genome order. (D) Median and IQR ELISpot responses to G-DDF (n = 3) and (E) F-EFY (n = 3) peptides are shown. P values are for 2-tailed Wilcoxon’s matched-pairs tests. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 7. Immunodominant epitopes from F and…
Figure 7. Immunodominant epitopes from F and G proteins induce proliferation and cytokine production in vitro.
(A) CFSE-stained PBMCs from uninfected HLA-matched donors were cultured with F-EFY, G-DDF, or DMSO and supplemented with IL-2 and IL-7. (B) CFSE dilution was analyzed by flow cytometry (n = 9). PBMCs from 6 representative donors expressing differing HLA alleles are shown. Blue histograms show cultures with peptide epitopes and red show DMSO negative controls. Median and individual data points of frequencies of CFSElo CD4+ T cells after stimulation are plotted. (C) PBMCs (n = 9) were restimulated after 10 days with peptide epitopes and assayed by intracellular staining for IFN-γ and flow cytometry. Medians and individual data points of IFN-γ+CD4+ T cell frequencies are plotted. Two-tailed Mann-Whitney test was used to compare RSV- and DMSO-only responses (**P < 0.01).
Figure 8. Epitope-specific CD4 + T cells…
Figure 8. Epitope-specific CD4+ T cells preferentially accumulate and express CXCR3 in the airway during acute RSV infection.
PBMCs from DPA1*01:03/DPB1*04:01–expressing individuals infected with RSV (n = 5) before infection and on day 10 were stained using DPB1*04:01/G-DDF tetramer and analyzed by flow cytometry. (A) FACS plots from 1 representative donor are shown, gated on CD3+ lymphocytes. (B) Cumulative data from blood (n = 11) and BAL (n = 7) are shown with P values for 2-tailed Mann-Whitney test comparing infected and uninfected groups, and 2-tailed Wilcoxon’s matched-pairs tests comparing time points. *P < 0.05, **P < 0.01, ***P < 0.001. PBMCs and BAL cells were costained with phenotypic markers of (C) T cell resident memory (CD69 and CD103), (D) proliferation/activation (Ki-67 and CD38), (E) memory subsets (CD45RA and CCR7), (F) costimulation (CD27 and CD28), homing receptors (G) CCR5 and CD62L and (H) CXCR3 and CCR4. FACS plots from 1 representative donor are shown, gated on CD3+CD4+ T lymphocytes. Red dots represent tetramer+ cells, and gray contours show total CD4+ T cells. The median frequencies of each subset are shown. Where not indicated with asterisks, differences were not statistically significant.

References

    1. Halle S, et al. In vivo killing capacity of cytotoxic T cells is limited and involves dynamic interactions and T cell cooperativity. Immunity. 2016;44(2):233–245. doi: 10.1016/j.immuni.2016.01.010.
    1. Wilkinson TM, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18(2):274–280. doi: 10.1038/nm.2612.
    1. Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15(3):185–189. doi: 10.1038/nri3803.
    1. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol. 2002;76(23):12388–12393. doi: 10.1128/JVI.76.23.12388-12393.2002.
    1. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852–856. doi: 10.1038/nature01441.
    1. Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54(1):15–39. doi: 10.1038/jhg.2008.5.
    1. Cole DK, et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol. 2007;178(9):5727–5734. doi: 10.4049/jimmunol.178.9.5727.
    1. Gebe JA, et al. Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur J Immunol. 2003;33(5):1409–1417. doi: 10.1002/eji.200323871.
    1. Sabatino JJ, Huang J, Zhu C, Evavold BD. High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J Exp Med. 2011;208(1):81–90. doi: 10.1084/jem.20101574.
    1. Shi T, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi: 10.1016/S0140-6736(17)30938-8.
    1. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163(4):693–698. doi: 10.1093/infdis/163.4.693.
    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–1759. doi: 10.1056/NEJMoa043951.
    1. Shi T, et al. The etiological role of common respiratory viruses in acute respiratory infections in older adults: a systematic review and meta-analysis [published online ahead of print March 8, 2019]. J Infect Dis .
    1. Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther. 2011;11(11):1455–1467. doi: 10.1517/14712598.2011.608062.
    1. McLellan JS, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–1117. doi: 10.1126/science.1234914.
    1. Openshaw PJM, Chiu C, Culley FJ, Johansson C. Protective and harmful immunity to RSV Infection. Annu Rev Immunol. 2017;35:501–532. doi: 10.1146/annurev-immunol-051116-052206.
    1. Falloon J, et al. An adjuvanted, postfusion f protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. J Infect Dis. 2017;216(11):1362–1370. doi: 10.1093/infdis/jix503.
    1. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 1991;88(3):1026–1033. doi: 10.1172/JCI115362.
    1. Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol. 2013;3(4):468–474. doi: 10.1016/j.coviro.2013.05.005.
    1. Alwan WH, Record FM, Openshaw PJ. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin Exp Immunol. 1992;88(3):527–536.
    1. Christiaansen AF, Knudson CJ, Weiss KA, Varga SM. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res. 2014;59(1-3):109–117. doi: 10.1007/s12026-014-8540-1.
    1. Crotty S. Follicular helper CD4 T cells (TFH) Annu Rev Immunol. 2011;29:621–663. doi: 10.1146/annurev-immunol-031210-101400.
    1. Chiu C, Openshaw PJ. Antiviral B cell and T cell immunity in the lungs. Nat Immunol. 2015;16(1):18–26. doi: 10.1038/ni.3056.
    1. Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015;21(7):688–697. doi: 10.1038/nm.3883.
    1. Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of resident memory CD8+ T cells. Nat Immunol. 2013;14(5):509–513. doi: 10.1038/ni.2568.
    1. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrançois L, Farber DL. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol. 2011;187(11):5510–5514. doi: 10.4049/jimmunol.1102243.
    1. Wu T, et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol. 2014;95(2):215–224. doi: 10.1189/jlb.0313180.
    1. Laidlaw BJ, et al. CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity. 2014;41(4):633–645. doi: 10.1016/j.immuni.2014.09.007.
    1. van Bleek GM, et al. Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells. J Virol. 2003;77(2):980–988. doi: 10.1128/JVI.77.2.980-988.2003.
    1. de Waal L, et al. Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J Virol. 2004;78(4):1775–1781. doi: 10.1128/JVI.78.4.1775-1781.2004.
    1. Guvenel AK, Chiu C, Openshaw PJ. Current concepts and progress in RSV vaccine development. Expert Rev Vaccines. 2014;13(3):333–344. doi: 10.1586/14760584.2014.878653.
    1. Habibi MS, et al. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015;191(9):1040–1049. doi: 10.1164/rccm.201412-2256OC.
    1. DeVincenzo JP, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182(10):1305–1314. doi: 10.1164/rccm.201002-0221OC.
    1. Jozwik A, et al. RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. Nat Commun. 2015;6:10224.
    1. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003;168(6):633–639. doi: 10.1164/rccm.200210-1148OC.
    1. Heidema J, et al. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol. 2004;85(pt 8):2365–2374.
    1. Mikhak Z, Strassner JP, Luster AD. Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. J Exp Med. 2013;210(9):1855–1869. doi: 10.1084/jem.20130091.
    1. Loebbermann J, et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol. 2012;5(2):161–172. doi: 10.1038/mi.2011.62.
    1. Christiaansen AF, et al. Altered Treg and cytokine responses in RSV-infected infants. Pediatr Res. 2016;80(5):702–709. doi: 10.1038/pr.2016.130.
    1. Kandasamy M, et al. RIG-I signaling is critical for efficient polyfunctional T cell responses during influenza virus infection. PLoS Pathog. 2016;12(7):e1005754. doi: 10.1371/journal.ppat.1005754.
    1. Akondy RS, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–7930. doi: 10.4049/jimmunol.0803903.
    1. Li X, et al. Ki-67 expression reveals strong, transient influenza specific CD4 T cell responses after adult vaccination. Vaccine. 2012;30(31):4581–4584. doi: 10.1016/j.vaccine.2012.04.059.
    1. González PA, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc Natl Acad Sci U S A. 2008;105(39):14999–15004. doi: 10.1073/pnas.0802555105.
    1. Munir S, et al. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog. 2011;7(4):e1001336. doi: 10.1371/journal.ppat.1001336.
    1. Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and α/β interferon responsiveness. J Virol. 2005;79(14):9315–9319. doi: 10.1128/JVI.79.14.9315-9319.2005.
    1. Lorente E, et al. Structural and nonstructural viral proteins are targets of T-helper immune response against human respiratory syncytial virus. Mol Cell Proteomics. 2016;15(6):2141–2151. doi: 10.1074/mcp.M115.057356.
    1. Levely ME, Bannow CA, Smith CW, Nicholas JA. Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. J Virol. 1991;65(7):3789–3796.
    1. Richards KA, Chaves FA, Sant AJ. Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. J Virol. 2009;83(13):6566–6577. doi: 10.1128/JVI.00302-09.
    1. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011;63(6):325–335. doi: 10.1007/s00251-011-0513-0.
    1. Boyoglu-Barnum S, et al. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice. J Virol. 2014;88(18):10569–10583. doi: 10.1128/JVI.01503-14.
    1. Fuentes S, Coyle EM, Golding H, Khurana S. Nonglycosylated G-protein vaccine protects against homologous and heterologous respiratory syncytial virus (RSV) challenge, while glycosylated G enhances RSV lung pathology and cytokine levels. J Virol. 2015;89(16):8193–8205. doi: 10.1128/JVI.00133-15.
    1. Holland CJ, et al. Enhanced detection of antigen-specific CD4+ T cells using altered peptide flanking residue peptide-MHC class II multimers. J Immunol. 2015;195(12):5827–5836. doi: 10.4049/jimmunol.1402787.
    1. Turner DL, et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 2014;7(3):501–510. doi: 10.1038/mi.2013.67.
    1. Collins N, et al. Skin CD4(+) memory T cells exhibit combined cluster-mediated retention and equilibration with the circulation. Nat Commun. 2016;7:11514.
    1. Mora JR, et al. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature. 2003;424(6944):88–93. doi: 10.1038/nature01726.
    1. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med. 2002;195(1):135–141. doi: 10.1084/jem.20011502.
    1. Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J Immunol. 2008;38(8):2168–2179. doi: 10.1002/eji.200838155.
    1. Zeremski M, et al. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol. 2011;55(3):545–553. doi: 10.1016/j.jhep.2010.12.033.
    1. Blauenfeldt T, et al. Interplay of DDP4 and IP-10 as a potential mechanism for cell recruitment to tuberculosis lesions. Front Immunol. 2018;9:1456.
    1. Ichikawa A, et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J Respir Crit Care Med. 2013;187(1):65–77. doi: 10.1164/rccm.201203-0508OC.
    1. Vojvoda V, et al. The increased type-1 and type-2 chemokine levels in children with acute RSV infection alter the development of adaptive immune responses. Biomed Res Int. 2014;2014:750521.
    1. Zhu J, et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. Chest. 2014;145(6):1219–1229. doi: 10.1378/chest.13-1567.
    1. Sidney J, et al. Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Curr Protoc Immunol. 2013;Chapter 18 doi: 10.1002/0471142735.im1803s100. Unit 18.3. doi:
    1. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2.
    1. Gulukota K, Sidney J, Sette A, DeLisi C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol. 1997;267(5):1258–1267. doi: 10.1006/jmbi.1997.0937.

Source: PubMed

3
Abonner